Big tech taking the lead, and driving the S&P 500 and Nasdaq to fresh record highs. How semis, software, and other sections of the tech trade can fuel your portfolio. Plus Fast Money’s Obesity Week coverage continues. Eli Lilly’s Chief Scientific Officer breaks down how the company’s obesity drug Zepbound performed in its first head-to-head clinical trial against Novo’s Wegovy, and what the results could mean for the weight loss drug wars.
Fast Money Disclaimer
Big tech taking the lead, and driving the S&P 500 and Nasdaq to fresh record highs. How semis, software, and other sections of the tech trade can fuel your portfolio. Plus Fast Money’s Obesity Week coverage continues. Eli Lilly’s Chief Scientific Officer breaks down how the company’s obesity drug Zepbound performed in its first head-to-head clinical trial against Novo’s Wegovy, and what the results could mean for the weight loss drug wars.
Fast Money Disclaimer
Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis
Dansk
Danmark